argenx SE (NASDAQ: ARGX) had its price target raised by analysts at Evercore ISI from $675.00 to $706.00. They now have an "outperform" rating on the stock.
argenx SE - American Depositary Shares (ARGX)
US:NASDAQ Investor Relations:
investor.argenx.com/phoenix.zhtml?c=254223&p=irol-presentations
Company Research
Source: MarketBeat
Impact Snapshot
Event Time:
ARGX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ARGX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ARGX alerts
High impacting argenx SE - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
ARGX
News
- argenx SE (NASDAQ: ARGX) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $675.00 price target on the stock, up previously from $646.00.MarketBeat
- argenx SE (NASDAQ: ARGX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $617.00 price target on the stock.MarketBeat
- argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory MyopathiesGlobeNewswire
- Is argenx SE (ARGX) the Best Immunotherapy Stock to Buy Now? [Yahoo! Finance]Yahoo! Finance
- argenx SE (NASDAQ: ARGX) was upgraded by analysts at Wolfe Research from a "peer perform" rating to an "outperform" rating. They now have a $697.00 price target on the stock.MarketBeat
ARGX
Earnings
- 10/31/24 - Beat
ARGX
Sec Filings
- 11/20/24 - Form 6-K
- 11/14/24 - Form SC
- 11/12/24 - Form SC
- ARGX's page on the SEC website